
Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

In the consolidated PBM industry, smaller companies say they can be nimble and not driven by rebates. But are they acquisition targets?

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

Suppliers of personal protective equipment have come up with innovative ways to meet the demand, but one expert notes the lack of rigorous research into its efficacy.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

What does it mean? When did it begin? How is it different from public health? Here are the answers to these questions and more.

Managed Healthcare Executive's October issue headlines 10 chosen healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

Managed Healthcare Executive's October issue headlines 10 chosen healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

Next month voters will weigh in on issues including dialysis centers, abortion, legalization of marijuana.

Francois de Brantes, Otis Brawley, Eric C. Hunter, Keely Macmillan, Ateev Mehrotra, and Marc Samuels are joining the Managed Healthcare Executive® editorial advisory board.

Darnell Dent, principal of Dent Advisory Services and a member of the Managed Healthcare Executive® Editorial Advisory Board, discusses health disparities for people of color - specifically Blacks and Latinos - and how COVID-19 has highlighted our failure at the intersection of public health, healthcare and social justice.

Sodium glucose co-transporter 2 (SGLT2) inhibitors have already remade the diabetes drug market. Now competition for new cardiac and renal indications is heating up among three of the main drugs in the class: Janssen’s Invokana (canagliflozin), AstraZeneca’s Farxiga (dapagliflozin), and Eli Lilly/Boehringer-Ingelheim’s Jardiance (empagliflozin).